导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.22% | 973/3712 |
| 近一周 | -0.96% | 1106/4228 |
| 近一月 | -3.37% | 1905/4196 |
| 近一季 | -7.97% | 2368/4044 |
| 近半年 | -3.66% | 1987/3824 |
| 近一年 | 9.74% | 902/3446 |
| 近两年 | 75.36% | 727/2399 |
| 近三年 | 40.81% | 574/1802 |
| 成立以来 | 60.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.12% 1050/4961 |
18.69% 1353/5312 |
- - |
- - |
| 2025 | 31.30% 1252/4813 |
2.22% 1435/3635 |
1.93% 2010/4076 |
24.48% 1464/4524 |
1.23% 1461/4813 |
| 2024 | 6.82% 1718/3463 |
-2.54% 1376/2808 |
-5.11% 1649/3014 |
15.99% 1571/3129 |
-0.41% 1416/3463 |
| 2023 | -5.45% 740/2656 |
7.68% 537/2280 |
-3.93% 971/2385 |
-4.40% 1136/2515 |
-4.39% 1005/2655 |
| 2022 | -17.48% 596/2207 |
-13.30% 729/1919 |
3.27% 1181/2016 |
-10.26% 373/2113 |
2.71% 856/2208 |
| 2021 | 17.65% 225/1822 |
-1.27% 459/1255 |
9.73% 525/1330 |
4.99% 304/1466 |
3.43% 434/1822 |
| 2020 | 25.06% 623/1250 |
-4.00% 333/1028 |
16.81% 411/1067 |
7.65% 767/1164 |
3.60% 902/1184 |
| 2019 | 26.99% 556/1092 |
31.06% 216/754 |
-9.77% 689/804 |
1.05% 434/850 |
6.26% 636/918 |
| 2018 | -30.09% 463/834 |
- - |
- - |
- - |
-11.45% 294/691 |
| 2017 | 1.09% 457/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.42% 374/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 天弘中证500ETF联接A VS. 长安沪深300非周期A(740101) |